I-CBP112

SKU: orb1303497

Description

I-CBP112 is a potent, cell-permeable small molecule that competitively inhibits the acetyl-lysine binding function of the CBP/p300 bromodomains. It serves as a valuable chemical probe for epigenetic research, enabling the study of bromodomain function in both cellular assays and in vivo models of cancer and inflammation.

Research Area

Epigenetics & Chromatin

Key Properties

• CAS Number: 1640282-31-0
• MW: 468.59
• Purity: 99.10% (May vary between batches)
• Formula: C₂₇H₃₆N₂O₅
• SMILES: CCC(=O)N1CCOc2c(C1)cc(cc2OC[C@H]1CCCN(C)C1)-c1ccc(OC)c(OC)c1
• Target: Epigenetic Reader Domain,Histone Acetyltransferase
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.27 mM);DMSO:55 mg/mL (117.37 mM)

Bioactivity

• Target IC50:
  CBP-p300 (Prostate cancer cells):9.1±1.2 μM (IC50)|CBP-p300 (Leukemia cells):5.5±1.1 μM (IC50)
• In Vivo:
  I-CBP112 markedly diminishes the leukemia-initiating potential of MLL-AF9+ AML cells in a dose-dependent manner [both in vitro and in vivo].
• In Vitro:
  Exposure to I-CBP112 in human and mouse leukemic cell lines significantly reduces colony formation and initiates cellular differentiation, without notable cytotoxic effects. When primary cells from the BioMAP panel were treated with I-CBP112, it elicited a distinctive cytokine and marker protein expression profile. Importantly, I-CBP112 markedly increases acetylation levels at histone H3K18 and H3K23 sites by p300, tripling H3K18ac levels. This compound not only enhances CBP-mediated acetylation at these locations but also at H4K5. The half-maximal effective concentration (EC50) for I-CBP112's action on p300 and CBP to increase H3K18 acetylation is approximately 2 μM.
• Cell Research:
  I-CBP112 is dissolved in DMSO and diluted with appropriate medium before use. Cells (6000 KG1a and 13000 LNCaP cells/well) are plated in 96-well flat-bottom plates approximately 24 h prior to drug treatment. After 24 h, 10–20% fetal bovine serum-containing medium is replaced with 2.5% serum medium, and cells are treated with I-CBP112 in 0.18% DMSO; 0.18% DMSO is shown to have negligible cell growth effects under the conditions used in our experiments. After being exposed to I-CBP112 for 66 h, cells are subjected to a final concentration of 0.476% [3H]thymidine per well and allowed to proliferate for an additional 6 h (exposure to I-CBP112 for a total of 72 h). Cells are harvested, and the counts of 3H in each well are taken relative to those treated with vehicle alone to quantify the effect of the ligand on proliferation.

Storage & Handling

• Storage: Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

EpigeneticReaderDomain, Epigenetic Reader Domain, HistoneAcetyltransferase, Histone Acetyltransferase, I CBP112, I-CBP 112, ICBP112, I-CBP112, I-CBP-112, HAT, HATs, inhibit, Inhibitor, CBP/p300( Leukemia cell)

Compound Identifiers

PubChem CID

90488984